New research highlights a growing shift toward more personalized and less aggressive treatment for Prostate Cancer, with a strong focus on improving patients’ quality of life. Doctors are moving away from a one-size-fits-all approach and using new data to identify which patients truly need intensive therapy and which may safely avoid certain treatments. Results from the POSEIDON study suggest that some men with very low PSA levels may be able to skip androgen deprivation therapy without affecting survival.
Researchers are also studying the best order and combinations of newer treatments. In the PEACE-3 trial, combining the radiopharmaceutical radium-223 with the hormone therapy enzalutamide improved survival, showing that some patients may benefit from receiving targeted therapies together rather than one after another. Other studies are exploring the use of drugs such as Lutetium-177 PSMA-617 earlier in the disease instead of reserving them for late stages.
Advanced imaging is also playing a key role. New scans such as PSMA-PET imaging can detect very small areas of cancer that standard scans might miss. In the INDICATE trial, doctors use these scans to guide treatment decisions, either keeping therapy standard when scans are negative or intensifying treatment when hidden cancer is detected. Experts say these approaches are helping doctors tailor therapy while reducing unnecessary side effects for many patients.